COO Cooper Companies Inc.

CooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility

CooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility

SAN RAMON, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) today announced the closing of a new five-year $2.14 billion senior unsecured credit facility, comprised of a $1.29 billion revolving line of credit and $850 million non-amortizing term loan. Proceeds from the refinancing will be used to retire all indebtedness under the Company’s existing $1.0 billion revolving line of credit and $1.0 billion term loan, as well as for general corporate purposes. The borrowing rates will be based on the Company’s leverage ratio, as defined in the Credit Agreement, and can range from LIBOR plus 0.75 percent to 1.5 percent. The initial borrowing rate is LIBOR plus 0.875 percent, which is 25 bps lower than the Company’s current borrowing rate. The Company also announced an amendment to its $500 million 364-day credit facility to match terms and conditions of the new facility where applicable. 

“We initiated this financing before COVID-19 became a pandemic, and I want to thank the banks who maintained their support during this time. In particular, KeyBank, which led the deal and did a fantastic job,” said President and CEO, Albert White. “This facility extends our maturity dates, reduces pricing and provides additional availability, reflecting the strength of Cooper.”

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663

EN
01/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies Appoints Barbara Carbone to Board of Directors

CooperCompanies Appoints Barbara Carbone to Board of Directors SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four...

 PRESS RELEASE

CooperCompanies Announces Release Date for Second Quarter 2025

CooperCompanies Announces Release Date for Second Quarter 2025  SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at . About Coo...

 PRESS RELEASE

CooperCompanies Announces First Quarter 2025 Results

CooperCompanies Announces First Quarter 2025 Results SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See ...

 PRESS RELEASE

CooperCompanies Announces Release Date for First Quarter 2025

CooperCompanies Announces Release Date for First Quarter 2025 SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at . About CooperCompaniesCooperCompanies (Nasdaq: C...

 PRESS RELEASE

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies to Present at the J.P. Morgan Healthcare Conference SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies’ website at . About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading globa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch